Home › First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017
 

Keywords :   


First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017

2015-08-19 07:01:19| drugdiscoveryonline Home Page

The first self-injectable antibody, PRO 140, has documented an impressive 98% success rate in a Phase 2b clinical trial for patients with HIV. In a monotherapy study, some HIV patients using PRO 140 are experiencing a completely suppressed viral load for 11 months.

Tags: in rate commercial trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Atlantic Tropical Weather Outlook
05.10Eastern North Pacific Tropical Weather Outlook
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
More »